Physician profile
Todd V Ingram
NPI 1245349414
$831.14
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $798 · 2020: $33.58.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $397.09 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $125.11 | 2019 | |
| Glaxosmithkline, LLC. | $91.64 | 2019-2020 | |
| Allergan, INC. | $41.98 | 2019 | |
| Janssen Pharmaceuticals, INC | $34.19 | 2019 | |
| Novo Nordisk INC | $33.15 | 2019 | |
| Amgen INC. | $31.25 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $24.20 | 2019 | |
| Amag Pharmaceuticals, INC. | $14.21 | 2019 | |
| Merck Sharp & Dohme LLC | $13.92 | 2019 | |
| Lilly USA, LLC | $13.41 | 2019 | |
| Pfizer INC. | $10.99 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Ingram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.